Analysts forecast Abbott Laboratories to post 1.6% earnings growth and 6%-8% revenue rise backed by recent acquisitions.
Abbott Laboratories (ABT) is set to release second-quarter results on July 15, with analysts projecting $1.28 earnings per share, a 1.6% increase from the prior period. Revenue growth of 6% to 8% is expected, driven by the Exact Sciences acquisition and strong performance in MedDevices and MedTech segments.
The consensus among analysts remains positive, with a Buy rating despite mixed revisions and recent stock underperformance. Baird analysts anticipate 8%-10% annual growth in MedDevices and accelerated MedTech revenue, supported by products like CancerGuard MCED and Cologuard, which could expand beyond $5bn annually if widely adopted.
Market expectations focus on the acquisition’s contribution to short- and medium-term growth, though the stock has lagged in recent months. Analysts highlight steady top-line expansion as a key driver for the quarter.